Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Frigault

Showing results (31-40 of 117) with videos related to

Pageof 12
Sort By:
Cancer|December 2, 2022
Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapyTejaswini M Dhawale, P Connor Johnson, Mahmoud R Gaballa, et al.
British Journal of Haematology|October 20, 2025
Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapyOsnat Itzhaki Ben Zadok, Panagiotis Simitsis, Caron Jacobson, et al.
Transplantation and Cellular Therapy|December 13, 2024
Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS DataMoataz Ellithi, Magdi Elsallab, Matthew A Lunning, et al.
Cytometry. Part B, Clinical Cytometry|April 29, 2021
Detection of CAR-T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratoriesUlrika Johansson, Kathleen Gallagher, Victoria Burgoyne, et al.
Acta Medica Academica|June 2, 2021
Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K VariantHarsha Trivedi, Omar Hamdani, Brittani Thomas, et al.
Blood|July 3, 2014
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cellsSonia Guedan, Xi Chen, Aviv Madar, et al.
Transplantation and Cellular Therapy|August 13, 2025
Safe and effective addition of ruxolitinib to graft-versus-host prophylaxis in older adults undergoing reduced-intensity allogeneic hematopoietic cell transplantationChristof C Smith, Jooho Chung, Areej El-Jawahri, et al.
The Oncologist|July 17, 2021
Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation RecipientsAnnabelle J Anandappa, Gabriela S Hobbs, Bimalangshu R Dey, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2021
Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell TherapyP Connor Johnson, Caron Jacobson, Alisha Yi, et al.
Cancer|September 11, 2019
Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphomaJeremy S Abramson, Kelly E Irwin, Matthew J Frigault, et al.
Pageof 12

Showing results (31-40 of 117) with videos related to

Sort By:
Pageof 12
Cancer|December 2, 2022
Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapyTejaswini M Dhawale, P Connor Johnson, Mahmoud R Gaballa, et al.
British Journal of Haematology|October 20, 2025
Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapyOsnat Itzhaki Ben Zadok, Panagiotis Simitsis, Caron Jacobson, et al.
Transplantation and Cellular Therapy|December 13, 2024
Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS DataMoataz Ellithi, Magdi Elsallab, Matthew A Lunning, et al.
Cytometry. Part B, Clinical Cytometry|April 29, 2021
Detection of CAR-T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratoriesUlrika Johansson, Kathleen Gallagher, Victoria Burgoyne, et al.
Acta Medica Academica|June 2, 2021
Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K VariantHarsha Trivedi, Omar Hamdani, Brittani Thomas, et al.
Blood|July 3, 2014
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cellsSonia Guedan, Xi Chen, Aviv Madar, et al.
Transplantation and Cellular Therapy|August 13, 2025
Safe and effective addition of ruxolitinib to graft-versus-host prophylaxis in older adults undergoing reduced-intensity allogeneic hematopoietic cell transplantationChristof C Smith, Jooho Chung, Areej El-Jawahri, et al.
The Oncologist|July 17, 2021
Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation RecipientsAnnabelle J Anandappa, Gabriela S Hobbs, Bimalangshu R Dey, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2021
Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell TherapyP Connor Johnson, Caron Jacobson, Alisha Yi, et al.
Cancer|September 11, 2019
Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphomaJeremy S Abramson, Kelly E Irwin, Matthew J Frigault, et al.
Pageof 12